Reduction of systemic exposure and side effects by intra-articular injection of anti-inflammatory agents for osteoarthritis: what is the safer strategy?

References

• Callahan LF, Ambrose KR, Albright AL, et al. Public health interventions for osteoarthritis-updates on the osteoarthritis action alliance’s efforts to address the 2010 OA public health agenda recommendations. Clin Exp Rheumatol. 2019;37(Suppl 120):31–39.
   PubMedGoogle Scholar
• Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol. 2011;7(1):43–49.
   PubMed Web of Science ®Google Scholar
• Aigner T, Soder S, Gebhard PM, et al. Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis–structure, chaos and senescence. Nat Clin Pract Rheumatol. 2007;3(7):391–399.
   PubMedGoogle Scholar
• Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580–592.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Osani M, Vaysbrot E, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578–1589.
   PubMed Web of Science ®Google Scholar
• Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–233.
   PubMed Web of Science ®Google Scholar
• Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 2003;163(2):169–178.
   PubMedGoogle Scholar
• Barker JD, Jrde Carle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. Ann Intern Med. 1977;87(3):299–301.
   PubMed Web of Science ®Google Scholar
• Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. Osteoarthr Cartil. 2018;26(3):293–295.
   PubMed Web of Science ®Google Scholar
• Yip K, Oettinger J. Why are we still using opioids for osteoarthritis? Int J Clin Pract. 2020;74(1):e13416.
   PubMed Web of Science ®Google Scholar
• Alamanda VK, Wally MK, Seymour RB, et al. Prevalence of opioid and benzodiazepine prescriptions for osteoarthritis. Arthritis Care Res (Hoboken). 2020;72(8):1081–1086.
   PubMed Web of Science ®Google Scholar
• Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707.
   PubMed Web of Science ®Google Scholar
• Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. 2013;146(3):185–196.
   PubMed Web of Science ®Google Scholar
• Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625–635.
   PubMed Web of Science ®Google Scholar
• Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5(2):77–94.
   PubMedGoogle Scholar
• Curtis E, Fuggle N, Shaw S, et al. Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):25–44.
   PubMed Web of Science ®Google Scholar
• Fibel KH, Hillstrom HJ, Halpern BC. State-of-the-art management of knee osteoarthritis. World J Clin Cases. 2015;3(2):89–101.
   PubMed Web of Science ®Google Scholar
• Primorac D, Molnar V, Matišić V, et al. Comprehensive review of knee osteoarthritis pharmacological treatment and the latest professional societies’ guidelines. Pharmaceuticals (Basel, Switzerland). 2021;14(3):205.
   PubMedGoogle Scholar
• Brophy RH, Fillingham YA. AAOS clinical practice guideline summary: management of osteoarthritis of the knee (nonarthroplasty), third edition. J Am Acad Orthop Surg. 2022;30(9):e721–e729.
   PubMed Web of Science ®Google Scholar
• Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59–66.
   PubMed Web of Science ®Google Scholar
• Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):18–21.
   PubMed Web of Science ®Google Scholar
• Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351–361.
   PubMedGoogle Scholar
• Miller JH, White J, Norton TH. The value of intra-articular injections in osteoarthritis of the knee. J Bone Joint Surg Br Vol. 1958;40-B(4):636–643.
   PubMedGoogle Scholar
• Conaghan PG, Hunter DJ, Cohen SB, et al. Effects of a single intra-articular injection of a microsphere formulation of triamcinolone acetonide on knee osteoarthritis pain: a double-blinded, randomized, placebo-controlled, multinational study. J Bone Joint Surg Am. 2018;100(8):666–677.
   PubMed Web of Science ®Google Scholar
• RESEARCH UCFDEA. Clinical pharmacology and biopharmaceutics review(s). Zilretta; [cited 2022 Jun 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208845Orig1s000ClinPharmR.pdf.
   Google Scholar
• Hunter DJ, Chang C-C, Wei JC-C, et al. TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study. Arthritis Res Ther. 2022;24(1):1–11.
   PubMed Web of Science ®Google Scholar
• Company TL. Extended and controlled release liposomal formulated dexamethasone for chronic knee OA pain. 2019 [updated Nov 26; cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT04123561.
   Google Scholar
• Evcik D, Maralcan G, Kuru I. The efficacy of intra-articular tenoxicam in the treatment of knee osteoarthritis. The Pain Clinic. 2003;15(4):405–408.
   Web of Science ®Google Scholar
• Unlu Z, Ay K, Tuzun C. Comparison of intra-articular tenoxicam and oral tenoxicam for pain and physical functioning in osteoarthritis of the knee. Clin Rheumatol. 2006;25(1):54–61.
   PubMed Web of Science ®Google Scholar
• Erbas M, Simsek T, Kiraz HA, et al. Comparison of the effectivity of oral and intra-articular administration of tenoxicam in patients with knee osteoarthritis. Rev Bras Anestesiol. 2015;65(5):333–337.
   PubMed Web of Science ®Google Scholar
• Yilmaz E. The evaluation of the effectiveness of intra-articular steroid, tenoxicam, and combined steroid–tenoxicam injections in the treatment of patients with knee osteoarthritis. Clin Rheumatol. 2019;38(11):3243–3252.
   PubMed Web of Science ®Google Scholar
• Bellamy JL, Goff BJ, Sayeed SA. Economic impact of ketorolac vs corticosteroid intra-articular knee injections for osteoarthritis: a randomized, double-blind, prospective study. J Arthroplasty. 2016;31(9 Suppl):293–297.
   PubMed Web of Science ®Google Scholar
• Park KD, Kim TK, Bae BW, et al. Ultrasound guided intra-articular ketorolac versus corticosteroid injection in osteoarthritis of the hip: a retrospective comparative study. Skeletal Radiol. 2015;44(9):1333–1340.
   PubMed Web of Science ®Google Scholar
• Xu J, Qu Y, Li H, et al. Effect of intra-articular ketorolac versus corticosteroid injection for knee osteoarthritis: a retrospective comparative study. Orthop J Sports Med. 2020;8(4):2325967120911126.
   Web of Science ®Google Scholar
• Jurgensmeier K, Jurgensmeier D, Kunz DE, et al. Intra-articular injections of the hip and knee with triamcinolone vs ketorolac: a randomized controlled trial. J Arthroplasty. 2021;36(2):416–422.
   PubMed Web of Science ®Google Scholar
• Lu L, Xie Y, Gan K, et al. Comparison of intra-articular injection of parecoxib vs oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis. World J Clin Cases. 2019;7(23):3971–3979.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Kano K, Nobuoka Y, et al. Sustained-release diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase 2 study. Rheumatology (Oxford). 2021;60(3):1435–1444.
   PubMed Web of Science ®Google Scholar
• SI-613 Study for Knee Osteoarthritis. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT03209362.
   Google Scholar
• Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT02803307.
   Google Scholar
• Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT03005873.
   Google Scholar
• Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT05139875.
   Google Scholar
• Nishida Y, Kano K, Nobuoka Y, et al. Efficacy and safety of diclofenac–hyaluronate conjugate (diclofenac etalhyaluronate) for knee osteoarthritis: a randomized phase III trial in Japan. Arthritis Rheumatol. 2021;73(9):1646–1655.
   PubMed Web of Science ®Google Scholar
• Yang N-Y, Suh J-H. The analgesic effect of knee intra-articular injection of lidocaine with aspirin on osteoarthritis of the knee. Korean J Pain. 1995;8(1):93–98.
   Google Scholar
• Knee Injection RCT. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT03694821.
   Google Scholar
• Unlu Z, Ay K. Intra-articular injection of tenoxicam in the treatment of osteoarthritis of the knee. J Musculoskelet Pain. 2006;14(4):37–47.
   Web of Science ®Google Scholar
• Grothe K, Flechsenhar K, Paehler T, et al. IκB kinase inhibition as a potential treatment of osteoarthritis–results of a clinical proof-of-concept study. Osteoarthr Cartil. 2017;25(1):46–52.
   PubMed Web of Science ®Google Scholar
• Wang J. Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: an open-label randomized controlled trial. J Int Med Res. 2018;46(1):326–334.
   PubMed Web of Science ®Google Scholar
• A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA). [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT04814368.
   Google Scholar
• Treatment of Knee Osteoarthritis With Intra-Articular Infliximab. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT01144143.
   Google Scholar
• Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT00303056.
   Google Scholar
• A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT01091116.
   Google Scholar
• Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee. [cited 2022 Jun 27]. Available from: https://ClinicalTrials.gov/show/NCT02205814.
   Google Scholar
• Hollander JL. Intrasynovial corticosteroid therapy in arthritis. Md State Med J. 1970;19(3):62–66.
   PubMedGoogle Scholar
• Caldwell JR. Intra-articular corticosteroids. Drugs. 1996;52(4):507–514.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Möllmann H, Grüner A, et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986;39(3):313–317.
   PubMed Web of Science ®Google Scholar
• Getgood A, Dhollander A, Malone A, et al. Pharmacokinetic profile of intra-articular fluticasone propionate microparticles in beagle dog knees. CARTILAGE. 2019;10(2):139–147.
   PubMed Web of Science ®Google Scholar
• Bonanomi M, Velvart M, Stimpel M, et al. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int. 1987;7(5):203–212.
   PubMed Web of Science ®Google Scholar
• Wu T-J, YW-N, Wu M-J, et al. Thu0465 pharmacokinetics and toxicokinetics studies of a sustained release liposomal formulation of dexamethasone sodium phosphate (tlc599) following intra-articular injection in dogs. Ann Rheum Dis. 2019;78:523.
   Google Scholar
• Kraus V, Conaghan P, Aazami H, et al. Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee. Osteoarthr Cartil. 2018;26(1):34–42.
   PubMed Web of Science ®Google Scholar
• Bertouch JV, Sallustio BC, Meffin PJ, et al. A comparison of plasma methylprednisolone concentrations following intra-articular injection in patients with rheumatoid arthritis and osteoarthritis. Aust N Z J Med. 1983;13(6):583–586.
   PubMedGoogle Scholar
• Derendorf H, Möllmann H, Voortman G, et al. Pharmacokinetics of rimexolone after intra-articular administration. J Clin Pharmacol. 1990;30(5):476–479.
   PubMed Web of Science ®Google Scholar
• Möllmann H, Rohdewald P, Schmidt E, et al. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol. 1985;29(1):85–89.
   PubMed Web of Science ®Google Scholar
• Albert KS, Brown SW, Desante KA, et al. Double Latin square study to determine variability and relative bioavailability of methylprednisolone. J Pharm Sci. 1979; 68(10):1312–1316.
   PubMed Web of Science ®Google Scholar
• Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res. 2003;9(1):3–24.
   PubMedGoogle Scholar
• Duclos M, Guinot M, Colsy M, et al. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc. 2007;39(7):1036–1043.
   PubMed Web of Science ®Google Scholar
• Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009;28(7):749–756.
   PubMed Web of Science ®Google Scholar
• Norcross BM, Winter JA. Methylprednisolone acetate: a single preparation suitable for both intra-articular and systemic use. NY State J Med. 1961;61:552–561.
   PubMedGoogle Scholar
• Schweitzer D, Le-Brun P, Krishnaswami S, et al. Clinical and pharmacological aspects of accidental triamcinolone acetonide overdosage: a case study. Neth J Med. 2000;56(1):12–16.
   PubMed Web of Science ®Google Scholar
• Flexion Therapeutics I. Clinical pharmacology and biopharmaceutics review (S. In: RESEARCH CFDEA, editor. 2016.
   Google Scholar
• Gondwe J, Davidson J, Deeley S, et al. Secondary cushing’s syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration. Rheumatology (Oxford). 2005;44(11):1457–1458.
   PubMed Web of Science ®Google Scholar
• Kumar S, Singh RJ, Reed AM, et al. Cushing’s syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004;113(6):1820–1824.
   PubMed Web of Science ®Google Scholar
• O’sullivan M, Rumfeld W, Jones M, et al. Cushing’s syndrome with suppression of the hypothalamic-pituitary-adrenal axis after intra-articular steroid injections. Ann Rheum Dis. 1985;44(8):561–563.
   PubMed Web of Science ®Google Scholar
• Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intra-articular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014;93(5):372–378.
   PubMed Web of Science ®Google Scholar
• Choudhry M, Malik R, Charalambous CP. Blood glucose levels following intra-articular steroid injections in patients with diabetes: a systematic. JBJS Rev. 2016;4(3):e5.
   PubMedGoogle Scholar
• Papavasiliou A, Isaac D, Marimuthu R, et al. Infection in knee replacements after previous injection of intra-articular steroid. J Bone Joint Surg Br. 2006;88(3):321–323.
   PubMedGoogle Scholar
• Chambers AW, Lacy KW, Liow MHL, et al. Multiple hip intra-articular steroid injections increase risk of periprosthetic joint infection compared with single injections. J Arthroplasty. 2017;32(6):1980–1983.
   PubMed Web of Science ®Google Scholar
• Schairer WW, Nwachukwu BU, Mayman DJ, et al. Preoperative hip injections increase the rate of periprosthetic infection after total hip arthroplasty. J Arthroplasty. 2016;31(9 Suppl):166–169. e1.
   PubMed Web of Science ®Google Scholar
• Brook EM, Hu CH, Kingston KA, et al. Corticosteroid injections: a review of sex-related side effects. Orthopedics. 2017;40(2):e211–e215.
   PubMed Web of Science ®Google Scholar
• Benyamin RM, Vallejo R, Kramer J, et al. Corticosteroid induced psychosis in the pain management setting. Pain Phys. 2008;6;11(12;6):917–920.
   Web of Science ®Google Scholar
• Sinha A, Dholakia M, Kothari G. Manic episode following epidural steroid injection: a case report. PM&R. 2013;5(9):S310–S311.
   Google Scholar
• Zeng C, Lane NE, Hunter DJ, et al. Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the osteoarthritis initiative. Osteoarthr Cartil. 2019;27(6):855–862.
   PubMed Web of Science ®Google Scholar
• Raynauld JP, Buckland‐Wright C, Ward R, et al. Safety and efficacy of long‐term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum. 2003;48(2):370–377.
   PubMed Web of Science ®Google Scholar
• McAlindon TE, LaValley MP, Harvey WF, et al. Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis a randomized clinical trial. JAMA. 2017;317(19):1967–1975.
   PubMed Web of Science ®Google Scholar
• Kompel AJ, Roemer FW, Murakami AM, et al. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology. 2019;293(3):656–663.
   PubMed Web of Science ®Google Scholar
• Gilsanz V, Bernstein B. Joint calcification following intra-articular corticosteroid therapy. Radiology. 1984;151(3):647–649.
   PubMed Web of Science ®Google Scholar
• Pal B, Morris J. Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists. Clin Rheumatol. 1999;18(3):264–265.
   PubMed Web of Science ®Google Scholar
• Cassidy JT, Bole GG. Cutaneous atrophy secondary to intra-articular corticosteroid administration. Ann Intern Med. 1966;65(5):1008–1018.
   PubMed Web of Science ®Google Scholar
• Gottlieb NL, Penneys NS, Brown HE. Periarticular perilymphatic skin atrophy: after intra-articular corticosteroid injections. JAMA. 1978;240(6):559–560.
   PubMed Web of Science ®Google Scholar
• Gupta A, Garg M, Johnson N, et al. Hypopigmentation after intra-articular corticosteroid injection. BMJ Case Rep. 2019;12(3):e228921.
   PubMedGoogle Scholar
• Habib GS, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol. 2010;29(4):347–356.
   PubMed Web of Science ®Google Scholar
• Stone S, Malanga GA, Capella T. Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain. Pain Physician. 2021;24(S1):233–246.
   PubMedGoogle Scholar
• Neander G, Eriksson LO, Wållin-Boll E, et al. Pharmacokinetics of intraarticular indomethacin in patients with osteoarthritis. Eur J Clin Pharmacol. 1992;42(3):301–305.
   PubMed Web of Science ®Google Scholar
• Zhang JX, Yan MQ, Li XH, et al. Local delivery of indomethacin to arthritis-bearing rats through polymeric micelles based on amphiphilic polyphosphazenes. Pharm Res. 2007;24(10):1944–1953.
   PubMed Web of Science ®Google Scholar
• Rabinow B, Werling J, Bendele A, et al. Intra-articular (IA) ropivacaine microparticle suspensions reduce pain, inflammation, cytokine, and substance P levels significantly more than oral or IA celecoxib in a rat model of arthritis. Inflamm. 2015;38(1):40–60.
   Google Scholar
• Petit A, Sandker M, Müller B, et al. Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomater. 2014;35(27):7919–7928.
   PubMed Web of Science ®Google Scholar
• Petit A, Redout EM, van de Lest CH, et al. Sustained intra-articular release of celecoxib from in situ forming gels made of acetyl-capped PCLA-PEG-PCLA triblock copolymers in horses. Biomater. 2015;53:426–436.
   PubMed Web of Science ®Google Scholar
• Park CW, Ma KW, Jang SW, et al. Comparison of piroxicam pharmacokinetics and anti-Inflammatory effect in rats after intra-articular and intramuscular administration. Biomol Ther (Seoul). 2014;22(3):260–266.
   PubMed Web of Science ®Google Scholar
• Kim HS, Cho HR, Ho MJ, et al. Determination of piroxicam from rat articular tissue and plasma based on LC–MS/MS. Arch Pharm Res. 2016;39(12):1653–1662.
   PubMed Web of Science ®Google Scholar
• Kim SR, Ho MJ, Kim SH, et al. Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection. Drug Des Devel Ther. 2016;10:3779–3787.
   PubMed Web of Science ®Google Scholar
• Akogwu EI, Saganuwan SA, Onyeyili PA. Comparative pharmacokinetics of piroxicam in male and female west African dwarf goats. Cogent Food Agric. 2017;3(1):1294444.
   Google Scholar
• Kim SH, Park KW, Kim JM, et al. Pharmacokinetics and four-week repeated-dose toxicity of hyaluronic acid and ketorolac combination following intra-articular administration in normal rats. Regul Toxicol Pharmacol. 2019;102:79–89.
   PubMed Web of Science ®Google Scholar
• Thing M, Lu Y, Agardh L, et al. Prolonged naproxen joint residence time after intra-articular injection of lipophilic solutions comprising a naproxen glycolamide ester prodrug in the rat. Int J Pharm. 2013;451(1–2):34–40.
   PubMedGoogle Scholar
• Blanco FJ, Guitian R, Moreno J, et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999;26(6):1366–1373.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40(9):1347–1365.
   PubMed Web of Science ®Google Scholar
• van Midwoud PM, Sandker M, Hennink WE, et al. In vivo pharmacokinetics of celecoxib loaded endcapped PCLA-PEG-PCLA thermogels in rats after subcutaneous administration. Eur J Pharm Biopharm. 2018;131:170–177.
   PubMed Web of Science ®Google Scholar
• Ma Y, Gao S, Hu M. Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1001:202–211.
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–473.
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med. 2006;119(3):255–266.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520–1528, 2 p following 1528.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284(10):1247–1255.
   PubMed Web of Science ®Google Scholar
• Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491–1502.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847.
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen A-M, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–814.
   PubMed Web of Science ®Google Scholar
• Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ cardiovasc Qual Outcomes. 2010;3(4):395–405.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–1104.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8(6):669–681.
   PubMed Web of Science ®Google Scholar
• Szeto C-C, Sugano K, Wang J-G, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020;69(4):617–629.
   PubMed Web of Science ®Google Scholar
• Baker M, Perazella MA. NSAIDs in CKD: are they safe? Am J Kidney Dis. 2020;76(4):546–557.
   PubMed Web of Science ®Google Scholar
• Shapiro PS, Rohde RS, Froimson MI, et al. The effect of local corticosteroid or ketorolac exposure on histologic and biomechanical properties of rabbit tendon and cartilage. Hand (NY). 2007;2(4):165–172.
   PubMedGoogle Scholar
• Dogan N, Erdem AF, Gundogdu C, et al. The effects of ketorolac and morphine on articular cartilage and synovium in the rabbit knee joint. Can J Physiol Pharmacol. 2004;82(7):502–505.
   PubMed Web of Science ®Google Scholar
• Selig DJ, Kress AT, Horton IM, et al. Pharmacokinetics, safety and efficacy of intra-articular non-steroidal anti-inflammatory drug injections for the treatment of osteoarthritis: a narrative review. J Clin Pharm Ther. 2022;47(8):1122–1133.
   Google Scholar
• Malemud CJ. Changes in proteoglycans in osteoarthritis: biochemistry, ultrastructure and biosynthetic processing. J Rheumatol Suppl. 1991;27:60–62.
   PubMedGoogle Scholar
• Dingle JT. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol. 1999;58(3):125–129.
   PubMed Web of Science ®Google Scholar
• El Hajjaji H, Marcelis A, Devogelaer J-P, et al. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol. 2003;30(11):2444–2451.
   PubMed Web of Science ®Google Scholar
• Mastbergen SC, Marijnissen AC, Vianen ME, et al. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatol (Oxford). 2006;45(4):405–413.
   PubMed Web of Science ®Google Scholar
• Rashad S, Revell P, Hemingway A, et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989;2(8662):519–522.
   PubMed Web of Science ®Google Scholar
• Huskisson EC, Berry H, Gishen P, et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK study group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J Rheumatol. 1995;22(10):1941–1946.
   PubMed Web of Science ®Google Scholar
• Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol. 1993;32(7):595–600.
   PubMedGoogle Scholar
• Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36(9):1196–1206.
   PubMedGoogle Scholar
• Reijman M, Bierma-Zeinstra SMA, Pols HAP, et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis?: the Rotterdam study. Arthritis Rheum. 2005;52(10):3137–3142.
   PubMed Web of Science ®Google Scholar
• Ding C, Cicuttini F, Jones G. Do NSAIDs affect longitudinal changes in knee cartilage volume and knee cartilage defects in older adults? Am J Med. 2009;122(9):836–842.
   PubMed Web of Science ®Google Scholar
• van Helvoort EM, Coeleveld K, Huisman AM, et al. Lack of a clear disease modifying activity of celecoxib in treatment of end-stage knee osteoarthritis: a rondomized observer blinded clinical trial. Osteoarthr Cartil. 2017;25:S420–S421.
   Web of Science ®Google Scholar
• Raynauld J-P, Martel-Pelletier J, Beaulieu A, et al. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum. 2010;40(3):185–192.
   PubMed Web of Science ®Google Scholar
• Bodor N. Novel approaches for the design of membrane transport properties of drugs. In: Roche EB, editor. Design of biopharmaceutical properties through prodrugs and analogs. Washington (DC): Academy of Pharmaceutical Sciences; 1977. p. 98–135.
   Google Scholar
• Bhardwaj YR, Pareek A, Jain V, et al. Chemical delivery systems and soft drugs: retrometabolic approaches of drug design. Saudi Pharm J. 2014;22(4):290–302.
   PubMed Web of Science ®Google Scholar
• Wu WM, Huang F, Lee Y, et al. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. J Pharm Pharmacol. 2008;60(3):291–297.
   PubMed Web of Science ®Google Scholar
• Albert A. Chemical aspects of selective toxicity. Nature. 1958;182(4633):421–422.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Soliman MR. Anti-inflammatory steroids without pituitary-adrenal suppression. Sci. 1982;215(4535):989–991.
   PubMed Web of Science ®Google Scholar
• Khan MOF, Park KK, Lee HJ. Antedrugs: an approach to safer drugs. Curr Med Chem. 2005;12(19):2227–2239.
   PubMed Web of Science ®Google Scholar
• P, Buchwald NB. Recent advances in the design and development of soft drugs. Pharmazie. 2014;69:403–413.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Ko DH. A novel approach to the discovery of non-systemic anti-inflammatory steroids; antedrug. Arch Pharm Res. 1999;22(3):279–287.
   PubMed Web of Science ®Google Scholar